Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) EPS (Basic) (2017 - 2025)

Historic EPS (Basic) for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to -$0.67.

  • Sutro Biopharma's EPS (Basic) fell 1355.93% to -$0.67 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.61, marking a year-over-year decrease of 6211.18%. This contributed to the annual value of -$2.96 for FY2024, which is 6635.32% down from last year.
  • As of Q3 2025, Sutro Biopharma's EPS (Basic) stood at -$0.67, which was down 1355.93% from -$0.14 recorded in Q2 2025.
  • Sutro Biopharma's 5-year EPS (Basic) high stood at $0.52 for Q4 2023, and its period low was -$0.95 during Q1 2024.
  • Over the past 5 years, Sutro Biopharma's median EPS (Basic) value was -$0.66 (recorded in 2021), while the average stood at -$0.58.
  • In the last 5 years, Sutro Biopharma's EPS (Basic) crashed by 32307.69% in 2022 and then surged by 18524.59% in 2023.
  • Sutro Biopharma's EPS (Basic) (Quarter) stood at -$0.83 in 2021, then grew by 26.51% to -$0.61 in 2022, then surged by 185.25% to $0.52 in 2023, then tumbled by 281.42% to -$0.94 in 2024, then rose by 28.98% to -$0.67 in 2025.
  • Its EPS (Basic) was -$0.67 in Q3 2025, compared to -$0.14 in Q2 2025 and -$0.79 in Q1 2025.